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Background: Neurological expertise in palliative care may be required not only for 
patients with primary neurological disorders but also for patients with non-neurological 
diseases suffering from burdensome neurological symptoms. The aim of this study was 
to determine the prevalence of neurological diagnoses and symptoms in palliative care 
patients, as well as the related burden and impact on everyday life.
Methods: We analyzed retrospectively the medical records of 255 consecutive patients 
from a tertiary medical center, at the time point of referral to an inpatient palliative care 
consultation service. In addition, 100 patients prospectively answered a questionnaire 
which included the assessment of neurological symptoms, as well as numeric rating 
scales for quality of life, symptom-specific burden, and restrictions in everyday life.
results: Forty-one patients (16%) suffered from a primary neurological disease. Most 
decisions regarding the termination of life-sustaining measures concerned this group 
(20/22, 91%). Neurological symptoms (excluding pain) were documented in 122 
patients (48%) with an underlying non-neurological disease. In the questionnaire study, 
98/100 patients reported at least one neurological or neuropsychiatric symptom, most 
frequently sleeping problems (N = 63), difficulty concentrating (N = 55), and sensory 
symptoms (N = 50). Vertigo/dizziness (N = 19) had the greatest impact on everyday 
life (7.57/10 ± 2.17) and the highest symptom-specific burden (7.14 ± 2.51). Difficulty 
concentrating (restrictions in everyday life/burden) and pain intensity were the only symp-
toms significantly correlated with quality of life (r = −0.36, p = 0.009/r = −0.32; p = 0.04; 
r = −0.327, p = 0.003).
conclusion: Neurological diseases and symptoms are frequent among palliative care 
patients and are often associated with a high symptom burden, which may severely 
affect the patients’ lives. It is thus of paramount importance to implement neurological 
expertise in palliative care.
Keywords: palliative care, neurological symptoms, prevalence, symptom burden, quality of life
inTrODUcTiOn
Palliative care aims to provide physical, psychosocial, and spiritual care for terminally ill patients 
and their families. Although differences between countries exist, palliative care has been linked 
traditionally to oncological diseases and internal medicine/oncology specialists still constitute the 
largest part of the palliative care workforce in many countries (e.g., Germany, USA, Japan, and 
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Canada) (1–4), while neurologists constitute less than 3% of 
physicians that are certified in palliative care (1, 2, 4). On the 
other hand, neurological and neurosurgical diseases have been 
found to be the second most common conditions in patients 
seen by a palliative care inpatient consultation service (5) and the 
most common diagnostic group in patients with non-malignant 
diseases (6).
Several reviews advocate a better integration of palliative care 
in the overall care of patients with neurological diseases (7–9). 
Both neurological and palliative care expertise are required, 
e.g., for patients with intracranial processes in order to assess 
prognosis, to substantiate decisions on the withholding or 
withdrawal of life-sustaining measures and to help the family 
understand the nature of an imminent persistent vegetative 
state or brain death. Although care concepts for people with 
motor neuron diseases may be an encouraging example of the 
successful integration of palliative care and neurology, many 
patients with neurodegenerative, neuro-oncological as well as 
neurovascular diseases still have a wide range of unmet pallia-
tive care needs (9, 10).
In addition, neurological expertise is required for non- 
neurological palliative care patients suffering from neurological 
symptoms. Scarce data are available on the prevalence of neu-
rological symptoms in a general palliative care population and 
most of the data have been assessed retrospectively. In a meta-
analysis looking at symptom prevalence in a total of 25,000 
patients with incurable cancer (11), “neurological symptoms” 
(without further specification) were documented in 15% of 
all patients and in 34% within their last 2 weeks of life. Even 
less is known about the relevance of neurological symptoms 
for the patients’ lives (e.g., their subjective burden, the impact 
on patients’ quality of life (QoL), or possible restrictions in the 
patients’ everyday lives). We therefore combined a review of 
patient charts with a prospective questionnaire study in order 
to gain an overview of the frequency of neurological symptoms 
as well as their clinical relevance in a general palliative care 
population.
MaTerials anD MeThODs
retrospective chart analysis
The charts of 255 consecutive patients who had been referred 
to the palliative care inpatient consultation service, were analyzed. 
Data were collected over a period of 9 months. Demographic 
data, diagnosis, reasons for current admission to the hospital, 
previous treatments as well as neurological and neuropsychi-
atric symptoms and preconditions—as listed in the patient 
charts prior to the referral to the palliative care team—were 
assessed.
Prospective Questionnaire study
A total of 100 consecutive inpatients, referred to the palliative 
care inpatient consultation service, who were willing to par-
ticipate and able to give their written informed consent were 
included in the questionnaire study. The questionnaire was 
administered in the form of a structured interview. The specific 
symptom burden is the degree to which the patients’ everyday 
lives were compromised by a symptom and the patients’ overall 
QoL were assessed using 0–10 point numeric rating scales 
(NRSs). NRS is a validated measure for QoL and is considered 
to assess the patient’s general QoL rather than only its health-
related aspects (12).
In order to differentiate lightheadedness or pre-syncopal 
syndromes from vertigo/dizziness, we asked the patients for the 
sensation of spinning/swaying and/or unsteady gait.
Actual pain intensity was assessed using a visual analog scale 
(VAS). To be able to compare the symptom “pain” with other 
neurological/neuropsychiatric symptoms, we assessed also the 
symptom-specific burden and restrictions in everyday life due to 
pain. Neuropathic pain was diagnosed by clinical assessment of 
the pain characteristics and the association with typical symp-
toms in the same area (e.g., tingling, numbness).
The “Confusion Assessment Method” (CAM) questionnaire 
was used when delirium was suspected. The CAM is a validated 
instrument for the diagnosis of delirium in a variety of medical 
settings (13, 14).
The Patient Health Questionnaire (PHQ-4) was used to screen 
patients for anxiety and depression.
In addition, patients were asked to name the symptoms, 
which were currently most distressing to them (max. 5). 
All patients who agreed received a structured neurological 
examination. Diagnostic workup of burdensome neurological 
symptoms was offered if indicated (e.g., neuro-otologic tests in 
patients with vertigo/dizziness). In addition, all patients were 
offered psychological support if desired. Descriptive statistics 
was performed using SPSS 24 (IBM, Chicago, IL, USA). 
Correlation analysis (Spearman’s rho) was performed. The 
study was carried out in accordance with the recommendations 
of the Ethics Committee of the Technical University Munich. 
The protocol was approved by the Ethics Committee of the 
Technical University Munich (No: 5682/13). All subjects gave 
written informed consent in accordance with the Declaration 
of Helsinki.
resUlTs
analysis of Patient charts
Reasons for Admission to the Hospital as 
Documented in the Patient Chart
Patients from nine different departments had been referred to 
the palliative care inpatient consultation service. For patient 
characteristics, see Table  1. In 84 out of 255 patients (33%), 
the main reasons or one of the main reasons for admission to 
the hospital were neurological symptoms (other than pain). 28 
patients (11%) had been admitted directly to the departments 
of neurology or neurosurgery. The presence of neurological 
symptoms and preconditions—as documented in the admission 
examination or discovered in other examinations during the 
hospital stay—was assessed. Patients were assigned to one of four 
groups. (10 patients remained unclassified due to incomplete data 
or unclear assignment):
TaBle 1 | Analysis of patients’ medical records: patients’ characteristics and 
neurological symptoms.
Patient characteristics 255 patients
Gender 118 (45%) female
Mean age 67 ± 13 years
Mean duration of disease 35 ± 54 months
Cancer diagnosis 217 (85%)
Primary brain tumor or cerebral metastases 49 (19%)
Previous surgery 138 (55%)
Previous chemotherapy 157 (63%)
Previous radiotherapy 100 (40%)
neurological symptoms as documented in the patient chart
Central paresis 41 (16%) Group 1: 25/41 (61%)
Group 2: 12/99 (12%)
Group 3: 4/23 (17%)
Seizures 27 (11%) Group 1: 22/41 (54%)
Group 2: 14/99 (14%)
Group 3: 1/23 (4%)
Dementia 14 (6%) Group 1: 10/41 (24%)
Group 2: 0/99 (0%)
Group 3: 4/23 (17%)
Confusion 47 (19%) Group 1: 15/41 (37%)
Group 2: 27/99 (27%)
Group 3: 4/23 (17%)
Other CNS symptoms 66 (26%) Group 1: 33/41 (80%)
Group 2: 27/99 (27%)
Group 3: 6/23 (26%)
Peripheral paresis 27 (11%) Group 1: 3/41 (7%)
Group 2: 20/99 (20%)
Group 3: 4/23 (17%)
Sensory symptoms 23 (9%) Group 1: 0/41 (0%)
Group 2: 20/99 (20%)
Group 3: 3/23 (13%)
Group 1: primary neurological condition, group 2: neurological symptoms presumably 
caused by a non-neurological underlying disease, and group 3: neurological symptoms 
presumably independent from the underlying disease.
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 (1) A neurological condition is the primary underlying disease 
(e.g., stroke, neurodegenerative disorder, primary brain 
tumor): 41 patients (16%)
 (2) Neurological symptoms (excluding pain) present and 
presumably caused by the (non-neurological) underlying 
disease and/or due to treatment of that disease: 99 patients 
(39%)
 (3) Neurological symptoms (excluding pain) present and 
presumably independent from the basic disease: 23 patients 
(9%)
 (4) No neurological preconditions or symptoms documented: 82 
patients (32%)
In most cases, no detailed neurological medical history had 
been assessed and no in-depth neurological examination had 
been performed before admission to the palliative care team. The 
most frequent neurological symptoms mentioned in the patient 
files are shown in Table 1. Neuropsychiatric symptoms such as 
sleeping problems, difficulty concentrating and impaired memory 
had not been assessed on a regular basis. “Taste abnormalities” 
were documented in none of the patient records.
Termination of Life-Sustaining Measures
After palliative care consultation, life-sustaining measures had 
been terminated in 22 patients, and 20 (91%) of them had been 
classified in group I (neurological condition as primary disease).
Patient Questionnaire study
Patient Characteristics
For the questionnaire study, 100 of 255 consecutive patients 
who were willing to participate and able to give their informed 
consent were included (50% female; 98 patients with cancer, 13 of 
them with brain metastases). 73 of 255 were not able to give their 
informed consent, 39 patients declined to participate, 32 patients 
could not be approached before the involvement of the pallia-
tive care consultation service, 11 lacked sufficient knowledge of 
the German language. None of the 41 neurologic patients could 
be recruited (20 were unconscious, 15 patients—mostly severe 
stroke or advanced glioblastoma—were conscious, but unable to 
consent, 5 refused to participate, and 1 lacked sufficient knowl-
edge of the German language). 98 patients reported at least one 
neurological or neuropsychiatric symptom excluding pain, 38 
patients stated that a neurologist or psychiatrist had treated them 
before admission to the hospital. Clinical neurological examina-
tion was performed after the patient interviews and objectified 
the symptoms reported (e.g., extent and degree of paresis or 
paresthesia). The values for “restrictions in everyday life” and 
“burden due to a specific symptom” were correlated, except for 
taste abnormalities.
Prevalence of Neurological Symptoms
The prevalence of neurological/neuropsychiatric symptoms, 
the symptom-specific burden, and restrictions in everyday life 
in patients participating in the questionnaire study is shown 
in Table 2. Sleeping problems (63/100), difficulties concentrat-
ing (55/100), and sensory symptoms (50/100) occurred most 
frequently. In addition, several neurological/neuropsychiatric 
symptoms were ranked among the most burdensome overall 
symptoms (Table 3).
Neurological Symptoms and QoL
The mean QoL (±SD) (NRS 0–10) of all patients was 3.7 (±2.3). 
The only neurological non-pain symptom significantly correla-
ted to QoL was difficulty concentrating (restrictions in everyday 
life: r = −0.36, p = 0.009; symptom-specific burden: r = −0.32; 
p = 0.04). In addition, the sum scores (restrictions in everyday 
life and symptom-specific burden) comprising the three most 
frequent neurological/neuropsychological symptoms (sleep-
ing problems, difficulty concentrating and sensory symptoms) 
were significantly correlated with QoL (r = −0.348, p = 0.0004; 
r = −0.322, p = 0.001).
Pain
52 patients reported having only one pain localization, 27 
patients reported having two, and 5 reported having three pain 
localizations. The most frequent type of pain was predominantly 
nociceptive (45 patients), followed by mixed pain (29 patients), 
and predominantly neuropathic pain (10 patients). Actual pain 
intensity—as measured by a VAS—correlated significantly with 
TaBle 3 | Most distressing symptoms at the time of the interview named by 100 
palliative care patients.
Frequency of mention symptoms
43× General weakness, pain
20× Dyspnea
13× Nausea, fatigue, loss of appetite
9× Being worried/rumination
5× Paresis
4× Loss of autonomy, social isolation, bleeding, 
concentration problems, dysphagia
3× sensory symptoms, vertigo/dizziness, diarrhea
2× Problems with stoma care, dysarthria,  
unsteady gait, anxiety, vision disturbances
fever
1× Restlessness, cough, sleep disturbances,  
ascites, edema
Neurological and neuropsychiatric symptoms as assessed in the questionnaire study 
are printed in bold.
TaBle 2 | Prevalence of symptoms, restrictions in everyday life and burden due 
to specific symptoms (NRS 0–10).
neurological symptoms n = 100 restrictions in 
everyday life
Mean (±sD)
Burden due 
to a specific 
symptom
Mean (±sD)
Pain 84 6.52 (±3.04) 6.48 (±3.08)
Sensory symptoms (numbness, 
tightness, tingling, burning)
50 4.67 (±3.27) 4.21 (±3.34)
Taste abnormalities 32 3.62 (±2.79) 5.62 (±2.83)
Hearing impairment 28 3.69 (±3.28) 3.85 (±3.16)
Muscular symptoms other than 
paresis (cramps, fasciculation)
28 NA NA
Vertigo/dizziness 19 7.57 (±2.17) 7.14 (±2.51)
Paresis 16 6.08 (±3.36) 6.06 (±3.2)
Coordination difficulties 12 6.58 (±3.26) 5.75 (±3.08)
Double images 10 6.00 (±3.2) 5.90 (±3.38)
Seizures 6 4.75 (±4.43) 5.00 (±4.08)
Speech disorders 4 4.00 (±3.65) 6.50 (±3.11)
neuropsychiatric symptoms
Sleeping problems 63 5.70 (±2.93) 5.64 (±3.34)
Difficulty concentrating 55 3.85 (±3.18) 4.44 (±3.12)
Impaired memory 44 3.36 (±3.21) 4.29 (±3.11)
symptoms with possible neurological causes
Bladder or bowel disorder 30 2.56 (±3.00) 3.90 (±3.56)
Dysarthria and/or dysphagia 22 6.27 (±3.10) 6.45 (±2.96)
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QoL (r = −0.327, p = 0.003). Restrictions in everyday life and 
subjective burden due to pain did not correlate significantly with 
patients’ QoL (r = −0.135, p = 0.21; r = −0.07, p = 0.517).
Depression and Anxiety (PHQ-4)
Normal scores (0–2) were found in 28 patients, mild distress 
(3–5) in 28 patients, moderate (6–8) in 23, and severe distress 
(9–12) in 21 patients. PHQ-4 showed a moderate correla-
tion with QoL (r = 0.271, p = 0.007). The PHQ-4 depression 
subscore was significantly correlated with the neuropsychologi-
cal symptom “difficulty concentrating” (r = 0.361 p = 0.003) and 
moderately, but significantly correlated with QoL (r = –0.271, 
p = 0.007).
Delirium
“Confusion” was documented in 47 patient charts (18.4%), 12 
were able to give their informed consent to study enrollment and 
underwent a screening test for delirium (CAM). The test-specific 
criteria for the diagnosis of “delirium” were fulfilled in 11 patients. 
No significant correlation with regard to age or gender was found 
in our study group.
DiscUssiOn
Several studies investigated the presence of burdensome symp-
toms in patients with advanced cancer and palliative care patients 
[for a review, see Ref. (11, 15)]. Isolated neurological symptoms 
such as agitation/delirium or vertigo/dizziness have been assessed 
in this context. However, a systematic and detailed analysis of 
neurological symptoms in palliative care patients has not been 
carried out before. We found that almost half of the palliative care 
patients without a primary neurological disease had neurological 
symptoms documented in their charts, and 98% of patients in the 
prospective study reported at least one burdensome neurological/
neuropsychological symptom. This is considerably higher than 
previously described (11). These findings have an immediate 
clinical relevance in that significant suffering arises from symp-
toms, which are underdiagnosed and therefore insufficiently 
treated. Our data suggest that this may be the case for a variety 
of neurological symptoms, which come with a high subjective 
burden and/or restrictions in everyday life, e.g., vertigo/dizziness, 
coordination difficulties, or double vision (Table 2).
sensory symptoms
The prevalence of sensory symptoms (numbness, tightness, 
tingling, and burning) reported in patients with advanced can-
cer and in palliative care patients varies widely from 6 to 36% 
(16–19). These variations may be caused by the different charac-
teristics of the populations investigated, but also by the differing 
assessment methods used. Not surprisingly, it has been found that 
the prevalence of many symptoms is considerably lower when 
assessed using medical records as compared with studies using 
questionnaires or structured interviews (11). Correspondingly, 
the prevalence of sensory symptoms in our questionnaire study 
(50%) was markedly higher than the results from the chart 
reviews (9%).
Dysgeusia
Similar results were obtained for the prevalence of “taste abnor-
malities” (dysgeusia) in palliative care patients: in our study, the 
occurrence of dysgeusia in the patients’ charts was 0%, while 
32% of patients in the questionnaire study reported taste abnor-
malities. Similarly, a previous interview study found that 86% of 
palliative care patients had taste abnormalities (20), while dys-
geusia was documented in only 1–2% of patients’ charts (17, 18).
Dizziness/Vertigo
Interestingly, our questionnaire study revealed “dizziness/vertigo” 
as the most burdensome symptom with the greatest impact on 
everyday life. “Vertigo”—defined as an erroneous sense of motion 
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and unsteadiness—is a relatively common condition, which also 
occurs in the general population: a survey in Germany reported 
a 12-month prevalence of 22.9% (21), while the point prevalence 
in palliative care patients with cancer was 10% (18). “Dizziness” 
is a term mostly used in a wider sense, which includes symptoms 
that range from a vague feeling of unsteadiness to severe vertigo. 
Pooled prevalence of dizziness in patients with incurable cancer 
was 17% in a previous study (11) and is similar to the occurrence 
found in our study (19%). Our questionnaire allowed only an ini-
tial screening for dizziness/vertigo without providing an accurate 
diagnosis. A detailed analysis of dizziness/vertigo in palliative 
care patients is urgently warranted, since effective treatment is 
available for many forms of this symptom (22).
Pain
Pain had a prevalence of 84% in our palliative care population 
with a high symptom-specific burden and relevance for everyday 
life. Actual pain intensity correlated significantly with QoL, 
while symptom-related burden and restrictions in everyday 
life due to pain did not. An association between pain and QoL 
has been described previously, using the “brief pain inventory” 
(23, 24), but also an NRS (25). In contrast to the VAS assessing 
actual pain intensity, our items asking for a “symptom-specific 
burden” or “restrictions in everyday life” implicate significant 
elements of personal judgment and/or coping and may therefore 
provide different results when correlated with QoL. 39% of our—
predominantly oncologic—patients suffered from neuropathic 
pain. This matches the prevalence of neuropathic pain in cancer 
patients assessed in palliative care (43%) and hospice settings 
(35%) (26). A recent review revealed that neuropathic pain in 
cancer patients is often insufficiently treated because of “incor-
rect use of co-analgesics” (27).
Delirium
In 47 (19%) patient charts from our cohort, “confusion” was 
documented. This percentage matches previous observations 
in a palliative care population (28). Since patients had to give 
informed consent to participate in the prospective study, only 
12 patients underwent CAM testing in the context of our study, 
which was positive in 11 patients. Prevalence, diagnosis, treat-
ment, and prognosis of confusion/delirium in palliative care 
patients have been widely studied (29). Recently, a randomized 
controlled trial showed that palliative care patients treated with 
standard neuroleptic medication had more delirium-specific 
symptoms, more side effects and a shorter survival rate than 
placebo-treated patients (30). This underscores the necessity of 
a careful diagnostic evaluation and individualized management 
of delirium in palliative care. Expertise in neuropharmacology 
and in the early detection of extra-pyramidal side effects of 
neuroleptic medication may be helpful to tailor treatment for 
these patients.
anxiety and Depression
Anxiety and depression are common symptoms in palliative 
care patients (31) with an estimated prevalence ranging between 
7 and 49% (32). Correspondingly, 21% of our patients scored 
9–12/12 in the PHQ, indicating severe psychological distress.
sleeping Problems
Similar to previous studies (33–35), sleeping problems were 
a frequent complaint among palliative care patients with a 
relatively high symptom-specific burden and impact on everyday 
activities. Sleep problems are multifactorial in many patients, 
although the moderate correlation with subjective burden due 
to pain suggests that inappropriate pain therapy may contribute 
to sleep disturbances in our patient population.
cognitive symptoms
A frequent occurrence of mild-to-moderate self-reported cog-
nitive symptoms, such as difficulty concentrating or memory 
disturbances, has been described previously in palliative care and 
cancer patients (16, 17). In addition, in a previous study, cancer 
outpatients named “difficulty concentrating” as one of the 13 top-
ranked symptoms (36). Correspondingly, difficulty concentrating 
was the only symptom (except pain) significantly correlated with 
QoL in our study. A previous report showed that complaints 
of difficulty concentrating did not correlate with objective 
measurements of cognitive function in palliative care patients 
(37). In our study group “difficulty concentrating” correlated 
significantly with the PHQ-4 depression subscore. It has been 
shown previously that the prevalence of depression in palliative 
care patients and patients with advanced cancer is greater than 
in the general population (38). Since difficulty concentrating is 
a complaint which is frequently associated with depression (39), 
this symptom may be part of a coexisting depressive syndrome. 
However, cognitive impairment and difficulty concentrating 
may also be accompanying symptoms of CNS processes or side 
effects of radiation therapy [for review, see Ref. (40)]. Expertise 
in organic forms of cognitive impairment may be helpful for the 
diagnostic classification of these symptoms in order to initiate 
appropriate treatment.
neurological/neuropsychological 
symptoms and Qol
The significant correlations between the sum scores of the three 
most frequently reported neurological/neuropsychiatric symp-
toms (sleeping problems, difficulty concentrating, and sen sory 
symptoms) and QoL, as well as the frequency at which neuro-
logical problems are reported to be one of the most distressing 
overall symptoms (Table  3), underscore the extent to which 
these symptoms may compromise the patients’ well-being. Many 
neurological symptoms that turned out to be burdensome in the 
questionnaire study had not been assessed prior to the referral to 
the palliative care team. This underlines previous findings that 
physicians frequently tend to focus on their specialized scope of 
practice rather than giving sufficient attention to burdensome 
(e.g., neurological) symptoms in severely ill patients (41).
Patients With Primary neurological 
Diagnoses
The percentage of patients with a primary neurological diag-
nosis (16%) in our retrospective cohort is higher than the 
proportions found in previous studies (9.2 and 8.8%) (5, 6); 
one of which however excluded patients with primary brain 
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tumors (5). In our study, the overwhelming majority (91%) of 
decisions regarding termination of life-sustaining measures 
(e.g., terminal extubation, termination of artificial hydration, 
and nutrition) were taken in patients with primary neurologi-
cal diseases. This is in line with the findings of Liu et al. (6), 
who showed that “eliciting goals of care” was the most frequent 
reason for palliative care consultations among neurological 
patients. In-depth knowledge of the course and prognosis of 
neurological diseases is indispensable when discussing treat-
ment options with the patients’ families. Generally, there is an 
increasing awareness that many patients suffering from neu-
rological diseases have palliative care needs (7, 8) and efforts 
have been made to improve the education of neurologists in 
this context (42).
neurological expertise in Palliative care
Given the high prevalence and the considerable burden of 
neurological symptoms in palliative care patients, as well as the 
relatively high percentage of patients with primary neurologi-
cal disorders, it becomes evident that neurological expertise is 
crucial in palliative care. It can be fostered by increased neu-
rological training in postgraduate palliative care education, as 
well as by recruiting neurologists in specialized palliative care 
centers. However, relatively few neurologists choose to abandon 
their primary specialty to concentrate on palliative medicine 
full-time. Clinical rotations of neurologists in palliative care 
teams may not only help to integrate neurological knowledge 
into palliative care, but also open up career options for young 
neurologists (2).
limitations
The single center design may limit the generalizability of the 
study. However, referral of patients from nine different depart-
ments of our university hospital resulted in a highly heterogene-
ous study population with a wide range of diagnoses. Our study 
was conducted in a tertiary medical center that has departments 
of neurology and neurosurgery. Therefore, the number of patients 
with primary neurological disorders may be higher than in less 
specialized hospitals. In the prospective cohort, 98% of patients 
suffered from cancer. The significance of the results from the 
questionnaire study may therefore apply primarily to oncological 
palliative care patients. Unfortunately, this also reflects the dis-
proportionate prevalence of tumor patients in most specialized 
palliative care centers worldwide.
Similar to other centers (43, 44) patients with non-malignant 
diseases including primary neurological disorders were referred 
to our palliative care consult service only at a very late stage. These 
patients were unable to consent and could not recruited for the 
prospective study. Similarly, patients of all disease stages and 
neurological symptoms that affected their ability to consent 
(e.g., delirium) were excluded from the study. Hence, the preva-
lence of neurologic symptoms in a general palliative care popula-
tion may be even higher and the symptoms more burdensome 
than found in our prospective study group.
Finally, the NRSs for the assessment of symptom-specific 
burden and for restrictions in everyday life used in our study 
had not been validated previously. However, NRSs allow for a 
direct comparison between specific neurological symptoms and 
help reducing the study burden for the severely ill patients to a 
minimum.
cOnclUsiOn
A majority of palliative care patients in our study suffered from 
neurological symptoms in varying degrees, frequently causing 
considerable symptom burden and restrictions in everyday life. 
Some of these symptoms are not well documented in patient 
charts and may remain undiagnosed and untreated. In addition, 
the question of withdrawal of life-sustaining treatment is most 
frequently posed in patients with primary neurological diseases. 
In consequence, palliative care teams are confronted on a daily 
basis with complex neurological questions and burdensome 
neurologic symptoms. This underscores the importance of the 
neurological expertise in palliative care teams.
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